^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Qibeian (iparomlimab/tuvonralimab)

    i
    Other names: PSB205 , PSB-205, PSB 205 , Anti-PD-1/CTLA-4 MabPair, QL1706, PBS-103/PBS-105, QL 1706, QL-1706
    Company:
    Qilu Pharma, Sound Biologics
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    1d
    QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P2/3, N=120, Not yet recruiting, Sun Yat-sen University
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Focus V (anlotinib) • Qibeian (iparomlimab/tuvonralimab)
    7d
    A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. (clinicaltrials.gov)
    P=N/A, N=59, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New trial
    |
    cyclophosphamide • epirubicin • Qibeian (iparomlimab/tuvonralimab)
    9d
    QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    12d
    A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P3, N=486, Not yet recruiting, Fujian Cancer Hospital
    New P3 trial
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    19d
    QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=34, Recruiting, Jiangsu Cancer Institute & Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Focus V (anlotinib) • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    22d
    Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair Deficiency (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2 trial • Mismatch repair • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Qibeian (iparomlimab/tuvonralimab)
    23d
    INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma (clinicaltrials.gov)
    P3, N=226, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting | Initiation date: Jun 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    28d
    NEO-ITHRAN: Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer (clinicaltrials.gov)
    P2, N=55, Recruiting, RenJi Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    29d
    A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, Jiangsu Cancer Institute & Hospital | Initiation date: Feb 2026 --> May 2026
    Trial initiation date
    |
    MSI (Microsatellite instability)
    |
    Avastin (bevacizumab) • capecitabine • oxaliplatin • irinotecan • Qibeian (iparomlimab/tuvonralimab)
    1m
    The exploration of iparomlimab and tuvonralimab combined with de-escalated chemotherapy as an innovative neoadjuvant treatment strategy for locally advanced cervical cancer: a case report from the NICE-CC trial. (PubMed, Front Immunol)
    In conclusion, this case highlights the potential of one cycle of neoadjuvant dual immunotherapy combined with standard chemotherapy, followed by two additional cycles of dual immunotherapy, for the treatment of LACC. This innovative treatment regimen warrants further investigation in the ongoing NICE-CC trial.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 negative
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    QL1706 Plus Lenvatinib in Previously Treated Penile Cancer (clinicaltrials.gov)
    P2, N=47, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lenvima (lenvatinib) • Qibeian (iparomlimab/tuvonralimab)
    1m
    SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors (clinicaltrials.gov)
    P2, N=30, Recruiting, Second Affiliated Hospital of Nanchang University | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)